Glaxo Taps Astex for Fragment-Based Discovery Deal Worth At Least $33 Mil.
Astex expects up to an additional $61 million in near-term milestones, and avoids the option-based structure that GlaxoSmithKline prefers.
Astex expects up to an additional $61 million in near-term milestones, and avoids the option-based structure that GlaxoSmithKline prefers.